Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.

@article{Jackson1998PharmacologicalEO,
  title={Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.},
  author={J. R. Jackson and Brian J. Bolognese and L. M. Hillegass and Shouki Kassis and Julian Adams and Don E. Griswold and James D. Winkler},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1998},
  volume={284 2},
  pages={687-92}
}
Chronic inflammatory diseases often are accompanied by intense angiogenesis, supporting the destructive proliferation of inflammatory tissues. A model of inflammatory angiogenesis is the murine air pouch granuloma, which has a hyperangiogenic component. In this model, we explored the regulation of inflammatory angiogenesis using SB 220025, a specific inhibitor of human p38 mitogen-activated protein (MAP) kinase, with an IC50 value of 60 nM and 50- to 1000-fold selectivity vs. other kinases… CONTINUE READING